The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis
Primary Purpose
Fangji Huangqi Pill, Knee Osteoarthritis
Status
Unknown status
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Fangji Huangqi pill or Fangji Huangqi pill placebo
Sponsored by
About this trial
This is an interventional treatment trial for Fangji Huangqi Pill
Eligibility Criteria
Inclusion Criteria:
- Meet the diagnostic criteria for knee osteoarthritis (American College of Rheumatology criteria)
- Grade 0-3 on the Kellgren-Lawrence grading system
- No serious medical history
- No known drug allergies
- No steroids, glucosamine, chondroitin sulfate, sodium hyaluronate before Fangji Huangqi pill treatment within 1 month
Exclusion Criteria:
- Combined with other disease such as rheumatoid arthritis, lupus arthritis and et. al
- Grade 4 on the Kellgren-Lawrence grading system
- Allergy to study drug
- Participating in other clinical trial
- Unwilling to give informed consent
Sites / Locations
- Longhua Hospital, Shanghai University of TCMRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Experimental group
Placebo group
Arm Description
Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
Outcomes
Primary Outcome Measures
change of the visual analogue scale (VAS)
change of the Western Ontario and McMaster university of orthopedic index
change of the Lequesne index
change of the 6 minutes walk test
Secondary Outcome Measures
change of the visual analogue scale (VAS)
change of the visual analogue scale (VAS)
change of the Western Ontario and McMaster university of orthopedic index
change of the Western Ontario and McMaster university of orthopedic index
change of the Lequesne index
change of the Lequesne index
change of the 6 minutes walk test
change of the 6 minutes walk test
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03173027
Brief Title
The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis
Official Title
The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis: a Study Protocol for a Randomized, Controlled Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 2018 (Anticipated)
Primary Completion Date
December 31, 2018 (Anticipated)
Study Completion Date
December 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Cui xuejun
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Knee osteoarthritis (KOA) is known as degenerative joint disease, which is the most common form of arthritis and the leading cause of disability, loss of function and pain worldwide. Effective therapy to manage RA is still lack at present. Fangji Huangqi pill (FHP) is a Chinese medicine which has been widely used in treating KOA in China for hundreds of years to relieve pain, reduce swelling and protect the affected joints from further degeneration. However, no certain evidence to show the effect of FHP for the management of active KOA.
Detailed Description
A randomized, double-blind, placebo-controlled clinical trials (RCT) will be conducted to explore whether the FHP could relieve pain and protect joints. 200 participants suffering from KOA will be enrolled and treated with FHP or placebo for 1 month. The primary outcome measures are the Visual analogue scale (VAS), Western Ontario and McMaster university of orthopedic index (WOMAC), the Lequesne index, and MOS Sleep Scale would be measured from the baseline to 1 month. The second outcome measures would be the six minutes walking test, the Short Form 36-item Health Survey (SF- 36), the X-ray of both knees, and the adverse events from the baseline to 2 weeks, 4 weeks, and 12 weeks' follow-up. In addition, the VAS score, the WOMAC score, the Lequesne index, and AIS Sleep Scale from the baseline to 2 weeks and 12 weeks' follow-up are also the second outcome measures.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Fangji Huangqi Pill, Knee Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Experimental group
Arm Type
Experimental
Arm Description
Drug: Fangji Huangqi pill 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill and Mobic
Arm Title
Placebo group
Arm Type
Placebo Comparator
Arm Description
Drug: Fangji Huangqi pill placebo 4g, twice a day, one month, oral Drug: Mobic 7.5mg, once a day, one month, oral participants should administrate both pill placebo and Mobic
Intervention Type
Drug
Intervention Name(s)
Fangji Huangqi pill or Fangji Huangqi pill placebo
Intervention Description
For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
Primary Outcome Measure Information:
Title
change of the visual analogue scale (VAS)
Time Frame
at 1 month
Title
change of the Western Ontario and McMaster university of orthopedic index
Time Frame
at 1 month
Title
change of the Lequesne index
Time Frame
at 1 month
Title
change of the 6 minutes walk test
Time Frame
at 1 month
Secondary Outcome Measure Information:
Title
change of the visual analogue scale (VAS)
Time Frame
from baseline to 2 weeks
Title
change of the visual analogue scale (VAS)
Time Frame
from baseline to 12 weeks
Title
change of the Western Ontario and McMaster university of orthopedic index
Time Frame
from baseline to 2 weeks
Title
change of the Western Ontario and McMaster university of orthopedic index
Time Frame
from baseline to 12 weeks
Title
change of the Lequesne index
Time Frame
from baseline to 2 weeks
Title
change of the Lequesne index
Time Frame
from baseline to 12 weeks
Title
change of the 6 minutes walk test
Time Frame
from baseline to 2 weeks
Title
change of the 6 minutes walk test
Time Frame
from baseline to 12 weeks
Title
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
Time Frame
from baseline to 2 weeks
Title
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
Time Frame
from baseline to 4 weeks
Title
change score of the Short Form 36-item Health Survey Questionnaire (SF-36)
Time Frame
from baseline to 12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Meet the diagnostic criteria for knee osteoarthritis (American College of Rheumatology criteria)
Grade 0-3 on the Kellgren-Lawrence grading system
No serious medical history
No known drug allergies
No steroids, glucosamine, chondroitin sulfate, sodium hyaluronate before Fangji Huangqi pill treatment within 1 month
Exclusion Criteria:
Combined with other disease such as rheumatoid arthritis, lupus arthritis and et. al
Grade 4 on the Kellgren-Lawrence grading system
Allergy to study drug
Participating in other clinical trial
Unwilling to give informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yongjun Wang, Doctor
Phone
86-189177763018
Email
yjwang8888@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Qianqian Liang, Doctor
Phone
86-021-64875390
Facility Information:
Facility Name
Longhua Hospital, Shanghai University of TCM
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qianqian Liang, Doctor
Phone
86-021-64875390
Email
liangqianqiantcm@126.com
First Name & Middle Initial & Last Name & Degree
Qiong Wang
Phone
86-13671779096
Email
13671779096@163.com
First Name & Middle Initial & Last Name & Degree
Yongjun Wang, Doctor
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis
We'll reach out to this number within 24 hrs